AI Article Synopsis
- This study investigated the impact of chronic use of antihypertensive medications (ACE inhibitors and ARBs) and cardiovascular comorbidities on mortality rates in COVID-19 patients.
- Results indicated that chronic use of ACE inhibitors may reduce mortality risk, while ARBs showed no significant effect.
- Importantly, older age and cardiovascular issues were significant risk factors, and timely treatment with low-molecular-weight heparin was found to be protective against mortality in hospitalized COVID-19 patients.
Article Abstract
Background: There is a great deal of debate about the role of cardiovascular comorbidities and the chronic use of antihypertensive agents (such as ACE-I and ARBs) on mortality on COVID-19 patients. Of note, ACE2 is responsible for the host cell entry of the virus.
Methods: We extracted data on 575 consecutive patients with laboratory-confirmed SARS-CoV-2 infection admitted to the Emergency Department (ED) of Humanitas Center, between February 21 and April 14, 2020. The aim of the study was to evaluate the role of chronic treatment with ACE-I or ARBs and other clinical predictors on in-hospital mortality in a cohort of COVID-19 patients.
Results: Multivariate analysis showed that a chronic intake of ACE-I was associated with a trend in reduction of mortality (OR: 0.53; 95% CI: 0.27-1.03; p = 0.06), differently from a chronic intake of ARB (OR: 1.1; 95% CI: 0.5-2.8; p=0.8). Increased age (ORs ranging from 3.4 to 25.2 and to 39.5 for 60-70, 70-80 and >80 years vs <60) and cardiovascular comorbidities (OR: 1.90; 95% CI: 1.1-3.3; p = 0.02) were confirmed as important risk factors for COVID-19 mortality. Timely treatment with low-molecular-weight heparin (LMWH) in ED was found to be protective (OR: 0.36; 95% CI: 0.21-0.62; p < 0.0001).
Conclusions: This study can contribute to understand the reasons behind the high mortality rate of patients in Lombardy, a region which accounts for >50% of total Italian deaths. Based on our findings, we support that daily intake of antihypertensive medications in the setting of COVID-19 should not be discontinued and that a timely LMWH administration in ED has shown to decrease in-hospital mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516574 | PMC |
| http://dx.doi.org/10.1016/j.ijcard.2020.09.062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary medication adherence in Medicare beneficiaries prescribed sacubitril-valsartan or renin-angiotensin system blockers for heart failure with reduced ejection fraction.
Am Heart J
December 2024
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Background: Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred over angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin-II-receptor blockers (ARBs) for treating heart failure with reduced ejection fraction (HFrEF). Primary medication adherence to a costly brand-name ARNI, compared to inexpensive generic ACE-Is or ARBs, is unknown.
Methods: This cohort study used a linked database of electronic health records and Medicare fee-for-service claims from a large integrated health care system in Boston to compare primary medication adherence among Medicare beneficiaries with HFrEF newly prescribed sacubitril-valsartan, those newly prescribed a generic ACE-I or ARB, and those switching from an ACE-I or ARB to sacubitril-valsartan.
Clinical Application of Pharmacogenomics in the Administration of Common Cardiovascular Medications.
Curr Rev Clin Exp Pharmacol
December 2024
Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Introduction: Genomic variations among individuals can greatly affect their responses to different medications. Pharmacogenomics is the area of study that aims to understand the relationship between these various genetic variations and subsequent drug responses. Many medications used to optimize cardiovascular health are affected by these genetic variants and these relationships can subsequently impact dosing strategies in patients.
View Article and Find Full Text PDFAvoiding anti-inflammatories: a randomised controlled trial testing the effect of an eHealth information package on primary healthcare patient medication knowledge and behaviour in Aotearoa New Zealand.
BMJ Open
November 2024
General Practice & Rural Health, University of Otago Dunedin School of Medicine, Dunedin, New Zealand.
Background: Patient medication knowledge and health literacy affect patient safety. Taking angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin II receptor blockers (ARBs), with diuretics and non-steroidal anti-inflammatory medications (NSAIDs) is nephrotoxic. Patients may not know of this risk.
View Article and Find Full Text PDFLooking for the ideal medication for heart failure with reduced ejection fraction: a narrative review.
Front Cardiovasc Med
September 2024
Cardiology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Article Synopsis
- The main goals of treating heart failure with reduced ejection fraction (HFrEF) are to lower mortality rates and reduce hospitalizations, while also improving the overall quality of life and cardiac function for patients.
- Effective treatments such as RAS inhibitors (ACE inhibitors, ARBs, ARNIs), beta-blockers, and SGLT2 inhibitors have shown benefits in reducing mortality, hospitalization, and the risk of sudden death, as well as aiding in cardiac remodeling and renal protection.
- The ideal HFrEF treatment should be effective across various patient profiles, taking into account individual differences and comorbidities, while maximizing overall health benefits beyond just heart function.
ACE Inhibitor and Angiotensin Receptor Blocker Use During Pregnancy: Data From the ESC Registry Of Pregnancy and Cardiac Disease (ROPAC).
Am J Cardiol
November 2024
Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address:
Angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are not recommended during the second and third trimester because of the significant risk of congenital anomalies associated with their use. However, data are scarce, especially regarding their use in the first trimester and about the impact of stopping just before pregnancy. Our study illustrates the profile of the women who used ACE-Is or ARBs during pregnancy and evaluates the impact on perinatal outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!